gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MREOHealthcarePharmaceuticals

Mereo BioPharma Group plc American Depositary Shares (MREO)

$0.3050−0.52%
Close Nov 12, 2026 · split-adjusted
Nov 12, 2026$0.30▼ 83.42% in range
Nov 12, 2025Low $0.24 · High $2.31Nov 12, 2026
What changed · written from our data
As of Nov 12, 2026

Mereo BioPharma Group plc American Depositary Shares closed at $0.30 on Nov 12, down 0.52%, 86.8% below its 52-week closing high. Volume of 708.1K shares was 1.12× its 20-day average (close to normal).

Split-adjusted performance: -1.5% over one month, +24.0% over six months, -83.7% over one year.

Short interest was 3.3M shares at the Oct 30 settlement, up 3.7% from the prior report (7.0 days to cover).

Market cap$48.7M159.7M shares
Revenue · quarter——
Diluted EPS——
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range0.24 – 2.31−86.8% from high
Volume708.1K1.12× 20-day avg
Volatility · 60d78.9%Annualised
Short % of float—7.0 days to cover
Net cash—
Next earnings—Not scheduled
Split-adjusted performance
1W +8.8%1M −1.5%3M −4.4%6M +24.0%YTD −26.8%1Y −83.7%3Y −86.0%5Y −87.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 419 companies (100 = best)

6-month momentum—
Revenue growth—
Net margin—
Value (low P/E)—
Size—

Industry medians: 6-month return −26.6%, revenue growth +10.0%, net margin −36.2%, P/E 17.1×.

Short interest

Details →
Shares short3.3M+3.7% vs prior
Days to cover7.0Settled Oct 30
% of float—
Short vol. 10d46.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MREOMereo BioPharma Group$0.3050−0.52%+24.0%———$48.7M
KZIAKazia Therapeutics Limited$6.95−6.46%−49.7%———$108.1MCompare
QNRXQuoin Pharmaceuticals$3.75−0.27%−35.5%———$18.0MCompare
AKTXAkari Therapeutics plc ADR (0.01 USD)$6.51−12.62%+75.9%———$14.9MCompare
CMMBChemomab Therapeutics Ltd. American Depositary Share$1.40+3.70%−17.6%———$11.3MCompare
BCYCBicycle Therapeutics$3.45−6.50%−26.1%+190.2%−30.8%—$241.8MCompare
AMRNAmarin$11.67−0.34%−21.0%−20.4%0.6%—$490.6MCompare
SLNSilence Therapeutics Plc American Depository Share$19.80+0.15%+177.7%———$1.23BCompare
CMPSCOMPASS Pathways Plc American Depository Shares$9.12−1.94%−14.1%———$1.29BCompare

News about Mereo BioPharma Group

All news →
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc. · Apr 3, 2026▼ NegativeINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREOGlobeNewswire Inc. · Mar 31, 2026▼ NegativeHolzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE)GlobeNewswire Inc. · Mar 24, 2026▼ NegativeMREO DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREOGlobeNewswire Inc. · Mar 22, 2026▼ NegativeROSEN, NATIONAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREOGlobeNewswire Inc. · Mar 13, 2026▼ Negative

Quick answers

What does Mereo BioPharma Group plc American Depositary Shares do?
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
What is MREO's market cap?
$48.71M, based on the Nov 12 close of $0.30.
What sector is MREO in?
Healthcare, in the Pharmaceuticals industry.

About Mereo BioPharma Group

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

HQ: London, 39 employeesListed Apr 24, 2018mereobiopharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology